Artificial intelligence in FDA regulatory correspondence, 2022 to 2026: a retrospective document analysis
George Kwiecinski, Reet Nandy (2026). Discover Pharmaceutical Sciences. https://doi.org/10.1007/s44395-026-00061-5
Abstract
This retrospective analysis searched the full text of all 3,011 FDA warning letters issued from January 2022 through September 2026 for references to artificial intelligence. Seven letters (0.23%) referred to AI: 3 device, 3 tobacco, and 1 drug. Only one, sent to Purolea Cosmetics Lab in April 2026, treated a firm's use of AI as a violation, citing AI-generated documents that lacked quality unit review under 21 CFR 211.22(c). One establishment inspection report and 2 Form FDA 483s also referred to AI.